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Abstract
Background: Neuropeptides may have considerable potential in the treatment of acute and chronic neurological
diseases. Encapsulated genetically engineered cells have been suggested as a means for sustained local delivery of
such peptides to the brain. In our experiments, we studied human mesenchymal stem cells which were
transfected to produce glucagon-like peptide-1 (GLP-1).
Methods: Cells were packed in a water-permeable mesh bag containing 400 polymeric microcapsules, each
containing 3000 cells. The mesh bags were either transplanted into the subdural space, into the brain parenchyma
or into the cerebral ventricles of the cat brain. Mesh bags were explanted after two weeks, and cell viability, as well
as GLP-1 concentration in the cerebrospinal fluid (CSF), was measured.
Results: Viability of cells did not significantly differ between the three implantation sites. However, CSF
concentration of GLP-1 was significantly elevated only after ventricular transplantation with a maximum
concentration of 73 pM (binding constant = 70 pM).
Conclusions: This study showed that ventricular cell-based delivery of soluble factors has the capability to achieve
concentrations in the CSF which may become pharmacologically active. Despite the controversy about the
pharmacokinetic limitations of ventricular drug delivery, there might be a niche in this for encapsulated cell
biodelivery of soluble, highly biologically-effective neuropeptides of low molecular weight like GLP-1.
Background
Neurotrophic peptides may have considerable potential in
the treatment of acute and chronic neurological diseases.
However, systemic delivery is limited by significant sys-
temic side effects, short plasma half-life or poor blood-
brain barrier passage. Therefore, local administration into
the central nervous system (CNS) has been proposed [1,2].
However, this drug delivery route, bypassing the blood
brain barrier, has been challenged, because substances are
rapidly removed from the brain through physiological
cerebrospinal fluid (CSF) outflow pathways [3-5].
Ex vivo gene therapy using encapsulated cell biodelivery
has been suggested as a way to achieve a more sustained
local delivery of proteins into the CNS. Bankable, non-
autologous cell lines cells can be used, that have been
genetically engineered to produce the protein. To prevent
host versus graft reaction, encapsulation of those cells
with permselective membranes has been introduced, to
allow diffusional nutrition and the outward passage of the
recombinant protein [6]. Encapsulation has been achieved
with different techniques, using either hollow fibers or
spherical polymeric microcapsules. Hollow fiber encapsu-
lated cells were investigated in clinical trials after implan-
tation into the lumbar subarachnoid space in chronic pain
[7] and ALS patients [8] as well as into the lateral ventricle
in Huntington’s disease patients [9]. While lumbar implan-
tation resulted in excellent cell viability and significant
lumbar CSF levels of the secreted soluble factors [7], ven-
tricular implantation has shown disappointing results with
variable numbers of surviving cells along with a markedly
low secretory rate [9]. Spherical microcapsules may
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any medium, provided the original work is properly cited.achieve improved viability rates because their shape pro-
vides almost ideal diffusion properties which can improve
the nutrition of encapsulated cells [10,11].
Glucagon-like peptide-1 (GLP-1) is a neuroprotective
substance which has been shown to protect neurons
from amyloid toxicity in vitro as well as in vivo in Alzhei-
mer’s disease models [12,13]. Recently, in a rat model of
traumatic brain injury, our group has demonstrated simi-
lar neuroprotective properties where GLP-1 was deliv-
ered from mesenchymal stem cells (MSC) encapsulated
in alginate microspheres. After intraventricular implanta-
tion of the cells, GLP-1 concentration in the CSF was
increased up to 17 pM, while no increased GLP-1 levels
were found after transplantation of MSC cell capsules
without GLP-1 secretion [14]. Using the same cell cap-
sules in a double transgenic mouse model of Alzheimer’s
disease, we found a significant anti-inflammatory effect
with GLP-1 engineered MSCs, but not with MSC without
GLP-1 secretion [15]. To provide further evidence for
encapsulated cell biodelivery of neurotrophic substances
for clinical applications, the present experiment investi-
gated the viability and secretory activity of cells as well as
the cisterna magna CSF level of GLP-1 after cerebral
transplantation of GLP-1 producing MSC in an animal
model with a larger brain. Three different implantation
sites in the cat brain were compared: intraventricular,
subdural and intraparenchymal.
Methods
Alginate microcapsules and mesh enclosure
A human, bone marrow-derived, mesenchymal stem cell
line, manufactured under good manufacturing practice
(GMP) conditions, was used in this study. It was immor-
talized by transduction with the human telomerase
reverse transcriptase (hTERT) gene [16]. After transfec-
tion with a plasmid vector encoding a GLP-1 fusion gene,
the cells produced an 8.7 kDa dimeric GLP-1 molecule.
The cells are embedded in a spherical shaped alginate
matrix (about 600 μm in diameter). The alginate matrix
is generated by cross-linking alginate with barium ions.
The alginate itself has no pharmacological effect but pro-
vides a mechanical scaffold for the cells and protects
them against attacks by the host’s immune system. Sub-
sequent to the alginate encapsulation process, the cell
capsules were stored in liquid N2 until usage. Each cap-
sule contained about 3000 cells. Alginate encapsulation
and cell engineering are proprietary manufacturing tech-
niques of CellMed AG, Alzenau, Germany (figure 1).
The alginate capsules containing the mesenchymal stem
cells were packed within a 1 × 1 cm sized, manually
sutured bag using a polypropylene mesh (MB-Mesh 40
Super Light, Medical Biomaterial Products GmbH, Ger-
many). For implantation, 400 ± 100 capsules were thawed
and filled into this mesh bag (figure 2). Transplantation
within the bag allows for the immobilization of the cell
capsules at different intracranial implantation sites. A vicryl
thread was attached to the mesh bag to allow retrieval.
Experimental protocol and surgical techniques
(implantation and explantation)
Thirteen cats (European Shorthair, Central Animal
Facility, Hannover, Medical School) were used for the
experiments. All experimental procedures were per-
formed under general anaesthesia. It was initiated by s.c.
injection of a ketaminhydrochloride / xylazine premedi-
cation (per kg: 0.1 ml Ketamin Gräub
®,D r .E .G r ä u b
AG, Bern, Switzerland; 0,05 ml Rompun
®, Bayer, Lever-
kusen, Germany). Subsequently the animals received
Figure 1 Illustration of cell encapsulation technology. Cells are embedded within a polymeric matrix, which is surrounded by an outer cell-
free capsule. Smaller molecules diffuse through the capsule, while at the same time, larger proteins and cells are excluded.
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®,B . B r a u nM e l s u n -
gen AG, Germany) and, after endotracheal intubation,
isoflurane 1.5-2.5% (Forene
®, Abbot, Baar, Switzerland).
All animals received an antibiotic prophylaxis for 10
days (extended-release penicillin und Dihydrostreptomy-
cin
®, Chassot) as well as an analgetic therapy 3 days
post operation (initially 4mg/kg, then 2mg/kg Carprofen
s.c., Buprenorphin 0.01mg/kg).
A 0.5 × 1.5 cm frontal craniotomy was performed under
sterile conditions below the temporal muscle insertion. A
straight dural opening 1.5 cm in length was made. The
mesh bag containing the microcapsules was implanted into
the subdural (n = 4), the frontal intraparenchymal (n = 5)
or the intraventricular (n = 4) space. After a frontal corti-
sectomy, a subcortical pocket was created for the intrapar-
enchymal placement and a transcortical approach to the
frontal horn for the intraventciular implantation of the cell
container. Care was given to sufficient hemostasis with
bipolar cautery. The dural opening was sealed with absorb-
able gelatin compressed sponge and the craniectomy was
closed with bone wax. The vicryl thread, which was
attached to the mesh implant, was incorporated into the
bone wax for fixation. The temporal muscle was then reap-
proximated using 0.3 vicryl sutures and skin was closed
with 0.3 monocryl sutures. Antibiotics were given for 10
days post-surgery. The animals were weighed and checked
for clinical and neurological symptoms on a daily basis.
Explantation of the mesh was performed after 14 days.
The implantation site was explored under general anaes-
thesia and, once the end of the thread attached to the
mesh beg was exposed, the implant was explanted with
gentle traction. Blood samples were taken by percuta-
neous puncture of a forelimb vein, and CSF was col-
lected by percutaneous puncture of the cisterna magna;
samples were taken in the subdural and intracerebral
implantation group only at day 14, and additionally in
the ventricular implantation group at days 0 and 7.
After centrifugation, a dipeptidyl peptidase IV inhibitor
was added (#DPP4, Biotrend), and the samples were fro-
zen at -80°C until the active GLP-1 was measured by
ELISA (Linco, EMD Millipore).
This study was conducted in accordance with the
German animal protection law and with the European
Communities Council Directive 86/609/EEC for the
protection of animals used for experimental purposes.
All experiments were approved by the Local Institu-
tional Animal Care and Research Advisory Committee
and permitted by the local government (33-42502-06/
1133).
Assessment of stem cell viability during and post-
implantation and histological assessment of the
implantation site
The explanted cell capsules were recultured and the post-
implantation GLP-1 production rate was determined by
active GLP-1 ELISA (Linco, EMD Millipore), and com-
pared with the GLP-1 secretion rate prior to implantation.
An amount of 10 capsules per explanted containment was
transferred into 1ml of culture medium (EMEM, 10%
BGS, 2mM L-glutamine) and incubated for 90 min. Cap-
sules were further assessed for viability with SYBR green/
propidium iodide staining. After intravital intracardiac
perfusion under deep anaesthesia, brains were removed
and fixed in 4% paraformaldehyde for histological analysis
with hematatoxylin and eosin (H&E) staining.
Results
GLP-1 CSF concentrations and stem cell viability
Table 1 summarizes GLP-1 concentrations in CSF and
blood plasma, comparing the measures after subdural,
intraparenchymal and intraventricular implantation. Cell
viability, as obtained by the GLP-1 production rate of
stem cells and by the SYBR Green/propidium iodide
staining at day 1 post-explantation, is also shown. Viabi-
lity of cells did not significantly differ between the three
implantation sites. Increased GLP-1 concentrations were
only found in the CSF, but not in the blood plasma, and
only after intra-ventricular implantation both at 7 and
14 days following implantation.
Histological findings at the implantation site
Gross macroscopic observation of the explanted brains
did not show any significant haemorrhages, midline
shifts or signs of infection at the surgical sites. None of
the animals exhibited acute occlusive hydrocephalus.
Figure 2 Diagram of the mesh enclosure. Several hundreds of cell-
containing capsules are packaged in a mesh enclosure that is
permeable to fluids. Volumetric flow of cerebrospinal or interstitial fluid
through the pores of the mesh supplies internal cells with oxygen and
nutrients.
Glage et al. Fluids and Barriers of the CNS 2011, 8:18
http://www.fluidsbarrierscns.com/content/8/1/18
Page 3 of 7Figure 3 shows representative H&E stains for all three
implantation sites. H&E staining did not reveal a major
local glial or inflammatory tissue response which could
have ensheathed the implants. Also, while showing some
minor fresh hemorrhages as a result of the surgical
retrieval of the mesh bag, the H&E staining ruled out
major local tissue injury.
Discussion
The present study investigates the CSF concentrations
of the GLP-1 peptide after implantation of GLP-1 pro-
ducing encapsulated MSC into the subdural, intrapar-
enchymal and intraventricular space of the cat brain.
While viability of cells retrieved after two weeks of
implantation did not differ between the implantation
sites, the levels of GLP-1 in the CSF were increased
after ventricular, but not after subdural or intraparench-
ymal transplantation. After ventricular implantation, the
measured CSF concentrations of GLP-1 reached the
level of the binding constant of the GLP-1 receptor [17].
GLP-1
GLP-1 is an endogenous insulin-stimulating peptide
secreted from the gastrointestinal tract in response to
food intake [18]. GLP-1 receptors are also expressed
throughout the mammalian brain [19]. Stimulation of
these receptors is associated with neuroprotective and
neurotrophic activity [12,13]. GLP-1 also improves
learning and memory, which was shown in GLP-1
receptor-deficient mice [20]. Because the plasma half-life
of GLP-1 averages only one to two min, the substance
must be locally delivered to the brain despite its good
blood brain barrier permeability [21].
We show here that encapsulated cell biodelivery can
achieve potentially therapeutic CSF concentration of
GLP-1. Our experimental design did not include control
groups i.e. capsules with mesenchymal cells but without
GLP-1 secretion, because previous experiments in
rodents have already shown that only GLP-1 engineered
cells, but not native MSCs, achieved increased CSF
levels of the peptide [14]. Furthermore, ELISA measure-
ments in the double transgenic mouse model of Alzhei-
mer’s disease revealed increased brain tissue
concentrations of GLP-1 only after transplantation of
GLP-1-secreting capsules. Interestingly, in the transgenic
mice a baseline level of GLP-1 was found in untreated
control animals as well as after transplantation of MSC
without GLP-1 secretion [15]. That increased CSF levels
could have resulted from the surgical implantation pro-
cedure and the related brain lesion in these experiments,
appears to be unlikely as in the traumatic brain injury
model we found no increased CSF level of GLP-1 as a
result of the brain damage alone [14].
Viability and secretory activity of retrieved cell capsules
In vitro experiments have shown that CSF can serve as a
carrier for cellular nutrients [22]. Accordingly, studies in
rodents have shown preserved viability and secretory
activity after cerebral long-term implantation of micro-
encapsulated cells [10,23]. In our cat experiments, we
found viability and recorded secretory rates in the
retrieved cells, which were as high as those after cere-
bral transplantation in rodents [14]. The present results
indicate that a volumetric flow rate of cerebrospinal or
interstitial fluid through the mesh pores exists and that
it is sufficient for in vivo nutrient and oxygen supply to
the encapsulated cells inside the mesh bag. Overall, the
highest viability and secretory rates were observed with
intraparenchymal transplantation, while after subdural
placement they were fairly low. Our present results cor-
respond well to our previous findings in rodents, show-
ing that the secretory activity decreases with the
implantation time [14]; future experiments must clarify
how long the secretory activity lasts.
Implantation site
The CSF concentration of GLP-1 was increased after intra-
ventricular, but not after subdural or intraparenchymal
Table 1 CSF and serum concentrations of glucagon-1 and cell viability following implantation of encapsulated
genetically-engineered stem cells into three intracerebral sites in cats
Implantation Site Subdural (n = 4) Intracerebral (n = 5) Intraventricular (n = 4)
CSF GLP-1 concentration [pM] 14d:
2.3/2.5/<2/2.2
14 d:
<2/<2/<2/<2/<2
Day zero: <2/<2/<2/<2
7d: NA**/63/6/73
14d: 47/44/8/<2
Serum GLP-1 concentration [pM] NA NA Day zero: <2.5(all)
7d: <2.5(all)
14 d: <2.5(all)
GLP-1 secretion prior to implantation (fmol/h/capsule) 3.6 (all) 4.6 (all) 4.6 (all)
GLP-1 secretion post implantation (fmol/h/capsule) NA*/ NA* / 0.6 / 3.0 1.6/ 1.2 / 1.6 / 1.7/ 3.5 0.9/ 1.6/ 1.5 / 1.9
Viability of cells / capsule (SYBRGreen/ propidium iodide) NA*/NA*/< 10%/40% 53%/58%/20%/83%/70% 41%/52%/51%/53%
NA: Examination not possible (* two bags were histologically investigated after intravital fixation, **CSF puncture not successful). 2.5 pM was the lowest limit of
the analysis method.
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examination of the brains and the different implantation
sites do not suggest that this is secondary to compartmen-
talization of the implant from local hemorrhage, glial scar-
ring or significant inflammation. Instead, the present
findings provide evidence suggesting that in order to obtain
efficient CSF concentration of its products, a cell implant
needs sufficient and large exposure to the CSF, and one
could argue that this would be obtained after intraventricu-
lar implantation.
The histological examination of the cat brains revealed
a relative large area of brain tissue damage as the result
of the implantation of the mesh bag. A clinical transla-
tion of this technique would not result in similar lesions,
just because of the much larger anatomical dimensions
of the human brain. In fact, in the human brain minimal
invasive surgical procedures, i.e. endoscopic surgery
could be used for the intraventricular implantation of
the cell capsules.
Intraventricular biodelivery with micro-encapsulation
techniques
While the intracerebroventricular administration of trophic
factors has influenced the pathology of neurodegenerative
disorders [24,2], the rapid clearance of CSF into the venous
circulation has been recognized as a substantial limitation
to the pharmakokinetics of this drug delivery route [4,25].
The only reported clinical study investigating intraventricu-
lar, hollow fiber encapsulated cell biodelivery revealed only
minimally increased CSF concentration of the delivered
factor [9]. The present experiments in a large animal
model, however, demonstrate that CSF concentrations up
to a therapeutic level can be achieved by ventricular trans-
plantation of cells secreting a soluble factor. This discre-
pancy can be explained by the different encapsulation
technique, i.e. hollow fiber encapsulation vs. micro-encap-
sulation. Micro-encapsulation, as used in our study, allows
for the transplantation of a significantly higher number of
cells, i.e. millions compared to only hundreds of thousands
in the hollow fiber encapsulation [26-28]. Thus, the higher
release rates that can be achieved with the micro-encapsu-
lation technique, compensate for the rapid CSF clearance,
and thereby help the build up of pharmacologically active
CSF factor concentrations. The viability and secretory
capacity of our cells at the time of explantation further sug-
gests that the sustained cell-based production of GLP-1
provides steady-state conditions despite a rapid CSF clear-
ance. Having achieved active CSF levels, substances may
diffuse into the brain interstitial fluid through the ependy-
mal layer bordering the ventricles. Substances may also be
rapidly moved via CSF flow tracks into the hemispheric
subarachnoid space, and from there into the brain tissue
along the perivascular spaces by means of a rapid convec-
tive transport mechanism [29]. These suggestions are sup-
ported by the finding that in primates, neurotrophic
growth factor can be widely distributed throughout the
brain to areas remote from the ventricular infusion site
[30]. As encapsulated cell biodelivery has achieved active
CSF levels of a soluble factor, this can be considered
Figure 3 Coronal cross-sections through the implantation site
(H&E stains). Minor fresh haemorrhages, as typical after microsurgery,
can be seen at the implantation site (arrows) following the
explantation procedure. No major gliotic, inflammatory or necrotic
areas are visible. Dashed arrows: surgical approach; * = lateral ventricle
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because of complex relationships between concentrations
in CSF and other brain compartments, CSF concentrations
may be difficult to interpret and may have limited value
[31]. However, considering our findings in the rodent
experiments which showed therapeutic GLP-1 effects after
ventricular encapsulated cell biodelivery, GLP-1 might be a
prototype for a substance qualified for cell-based delivery
into the CSF for the following reasons:
- Its small molecular weight facilitates diffusional
and convective distribution through the brain tissue.
- Pharmacological activity is already achieved at con-
siderably low drug concentrations in the picomolar
range.
- A sustained delivery may be achieved with encap-
sulated cell biodelivery.
Despite the controversy about ventricular drug deliv-
ery and the discussed pharmacokinetic limitations, there
might be a niche in this for encapsulated cell biodelivery
of soluble, highly biologically-effective neuropeptides of
low molecular weight like GLP-1.
The possibility to explant stem cell transplants from
the brain could be an important safety aspect in a clini-
cal application. While retrieval of hollow fibers has been
described [1,6], there is currently no non-invasive tech-
nique available for the explantation of polymeric micro-
capsules. Our report is the first to describe a practical
technique for the retrieval of microcapsules. We assume
that volumetric flow of cerebrospinal or interstitial fluid
through the water-permeable mesh permits the diffu-
sional nutrient and oxygen supply for the enclosed cell-
containing capsules. Nonetheless, we are aware that the
mesh may hamper the cell viability, particularly if the
mesh pores are obstructed with invading cells and fibrin
and blood clot layers, a finding well known as a cause
for ventricular catheter obstruction. This partial clogging
of the mesh pores may therefore be responsible for the
observed inter-individual variability of viability and
GLP-1 secretion rate seen in these experiments.
Conclusion
This study has shown that cell-based delivery of soluble
factors into the cerebral ventricles can achieve pharma-
cologically active concentrations in the CSF. This find-
ing provides the rationale to pursue the objectives with
ventricular drug delivery, particularly to look for possi-
ble therapeutic effects of encapsulated cell biodelivery in
large animal models of neurological diseases.
Acknowledgements
This study was supported by the German Federal Ministry of Education and
Research and the Neurobionics Foundation Hannover, Germany.
Author details
1Institute for Laboratory Animal Science and Central Animal Facility,
Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
2Neurosurgery Foundation, 55 Claverick Str., Providence, RI 02903, USA.
3International Neuroscience Institute, Rudolf-Pichlmayrstr. 4, 30625 Hannover,
Germany.
4CellMed AG, Industriestrasse 19, 63755 Alzenau, Germany.
Authors’ contributions
SG, TB and HJH performed and contributed to the animal experiments; SG,
TB, MM and PK contributed to conception, data analysis and preparation of
the manuscript, and CW and PG developed and manufactured the cell
capsules.
All authors have read and approved the final version of the manuscript.
Competing interests
C.W. and P.G. are employed by CellMedAG and T.B. is consultant to CellMed
AG, which is the company manufacturing the encapsulated cells.
Received: 28 January 2011 Accepted: 17 May 2011
Published: 17 May 2011
References
1. Tseng JL, Aebischer P: Encapsulated neural transplants. Prog Brain Res
2000, 127:189-202.
2. Thorne RG, Frey WH: Delivery of neurotrophic factors to the central
nervous system: pharmacokinetic considerations. Clin Pharmacokinet
2001, 40:907-946.
3. Lo EH, Singhal AB, Torchilin VP, Abbott NJ: Drug delivery to damaged
brain. Brain Res Brain Res Rev 2001, 38:140-148.
4. Aird RB: A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp
Neurol 1984, 86:342-358.
5. Pardridge WM: Drug transport in brain via the cerebrospinal fluid. Fluids
Barriers CNS 2011, 8:7.
6. Lindvall O, Wahlberg LU: Encapsulated cell biodelivery of GDNF: a novel
clinical strategy for neuroprotection and neuroregeneration in
Parkinson’s disease? Exp Neurol 2008, 209:82-88.
7. Buchser E, Goddard M, Heyd B, Joseph JM, Favre J, de Tribolet N,
Lysaght M, Aebischer P: Immunoisolated xenogenic chromaffin cell
therapy for chronic pain. Initial clinical experience. Anesthesiology 1996,
85:1005-1012.
8. Zurn AD, Henry H, Schluep M, Aubert V, Winkel L, Eilers B, Bachmann C,
Aebischer P: Evaluation of an intrathecal immune response in
amyotrophic lateral sclerosis patients implanted with encapsulated
genetically engineered xenogeneic cells. Cell Transplant 2000, 9:471-484.
9. Bloch J, Bachoud-Levi AC, Deglon N, Lefaucheur JP, Winkel L, Palfi S,
Nguyen JP, Bourdet C, Gaura V, Remy P, et al: Neuroprotective gene
therapy for Huntington’s disease, using polymer-encapsulated cells
engineered to secrete human ciliary neurotrophic factor: results of a
phase I study. Hum Gene Ther 2004, 15:968-975.
10. Murua A, Portero A, Orive G, Hernandez RM, de Castro M, Pedraz JL: Cell
microencapsulation technology: towards clinical application. J Control
Release 2008, 132:76-83.
11. Orive G, Hernandez RM, Rodriguez Gascon A, Calafiore R, Chang TM, de
Vos P, Hortelano G, Hunkeler D, Lacik I, Pedraz JL: History, challenges
and perspectives of cell microencapsulation. Trends Biotechnol 2004,
22:87-92.
12. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH: Protection and
reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and
exendin-4. J Pharmacol Exp Ther 2002, 302:881-888.
13. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH:
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide
(Abeta) levels and protects hippocampal neurons from death induced
by Abeta and iron. J Neurosci Res 2003, 72:603-612.
14. Heile AM, Wallrapp C, Klinge PM, Samii A, Kassem M, Silverberg G, Brinker T:
Cerebral transplantation of encapsulated mesenchymal stem cells
improves cellular pathology after experimental traumatic brain injury.
Neurosci Lett 2009, 463:176-181.
15. Klinge P, Harmening K, Miller MC, Heile A, Wallrapp C, Geigle P, Brinker T:
Encapsulated native and Glucagon-like peptide-1 transfected human
mesenchymal stem cells in a transgenic mouse model of Alzheimer’s
disease. Neurosci Lett 2011.
Glage et al. Fluids and Barriers of the CNS 2011, 8:18
http://www.fluidsbarrierscns.com/content/8/1/18
Page 6 of 716. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI,
Jensen TG, Kassem M: Telomerase expression extends the proliferative
life-span and maintains the osteogenic potential of human bone
marrow stromal cells. Nat Biotechnol 2002, 20:592-596.
17. Beak SA, Heath MM, Small CJ, Morgan DG, Ghatei MA, Taylor AD,
Buckingham JC, Bloom SR, Smith DM: Glucagon-like peptide-1 stimulates
luteinizing hormone-releasing hormone secretion in a rodent
hypothalamic neuronal cell line. J Clin Invest 1998, 101:1334-1341.
18. Drucker DJ: Biological actions and therapeutic potential of the glucagon-
like peptides. Gastroenterology 2002, 122:531-544.
19. Campos RV, Lee YC, Drucker DJ: Divergent tissue-specific and
developmental expression of receptors for glucagon and glucagon-like
peptide-1 in the mouse. Endocrinology 1994, 134:2156-2164.
20. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ,
Klugmann M, Banks WA, Drucker DJ, et al: Glucagon-like peptide-1
receptor is involved in learning and neuroprotection. Nat Med 2003,
9:1173-1179.
21. Holst JJ: Glucagon-like peptide-1: from extract to agent. The Claude
Bernard Lecture, 2005. Diabetologia 2006, 49:253-260.
22. Miyan JA, Zendah M, Mashayekhi F, Owen-Lynch PJ: Cerebrospinal fluid
supports viability and proliferation of cortical cells in vitro, mirroring in
vivo development. Cerebrospinal Fluid Res 2006, 3:2.
23. Visted T, Lund-Johansen M: Progress and challenges for cell
encapsulation in brain tumour therapy. Expert Opin Biol Ther 2003,
3:551-561.
24. Fumagalli F, Racagni G, Riva MA: The expanding role of BDNF: a
therapeutic target for Alzheimer’s disease? Pharmacogenomics J 2006,
6:8-15.
25. Lo EH, Singhal AB, Torchilin VP, Abbott NJ: Drug delivery to damaged
brain. Brain Res Brain Res Rev 2001, 38:140-148.
26. Schwenter F, Schneider BL, Pralong WF, Deglon N, Aebischer P: Survival of
encapsulated human primary fibroblasts and erythropoietin expression
under xenogeneic conditions. Hum Gene Ther 2004, 15:669-680.
27. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR,
Bush RA: Ciliary neurotrophic factor (CNTF) for human retinal
degeneration: phase I trial of CNTF delivered by encapsulated cell
intraocular implants. Proc Natl Acad Sci USA 2006, 103:3896-3901.
28. Mittoux V, Joseph JM, Conde F, Palfi S, Dautry C, Poyot T, Bloch J,
Deglon N, Ouary S, Nimchinsky EA, et al: Restoration of cognitive and
motor functions by ciliary neurotrophic factor in a primate model of
Huntington’s disease. Hum Gene Ther 2000, 11:1177-1187.
29. Guan J, Beilharz EJ, Skinner SJ, Williams CE, Gluckman PD: Intracerebral
transportation and cellular localisation of insulin-like growth factor-1
following central administration to rats with hypoxic-ischemic brain
injury. Brain Res 2000, 853:163-173.
30. Emmett CJ, Stewart GR, Johnson RM, Aswani SP, Chan RL, Jakeman LB:
Distribution of radioiodinated recombinant human nerve growth factor
in primate brain following intracerebroventricular infusion. Exp Neurol
1996, 140:151-160.
31. de Lange EC, Danhof M: Considerations in the use of cerebrospinal fluid
pharmacokinetics to predict brain target concentrations in the clinical
setting: implications of the barriers between blood and brain. Clin
Pharmacokinet 2002, 41:691-703.
doi:10.1186/2045-8118-8-18
Cite this article as: Glage et al.: Therapeutic concentrations of glucagon-
like peptide-1 in cerebrospinal fluid following cell-based delivery into
the cerebral ventricles of cats. Fluids and Barriers of the CNS 2011 8:18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Glage et al. Fluids and Barriers of the CNS 2011, 8:18
http://www.fluidsbarrierscns.com/content/8/1/18
Page 7 of 7